FIGURE 1.

Illustration of the molecular and clinical effects of GLP-1 receptor agonists. In the uppermost row, a depiction of organs and structures impacted by GLP-1 receptor agonists is presented. Each of these organs exhibits distinct molecular effects. This term covers the outcomes arising either directly or indirectly from the influence of GLP-1 receptor agonists on these organs. In the lower section in the yellow boxes, the clinical effects are described and from what organ they are influenced. Abbreviations: BMI, body mass index; GLP-1, glucagon-like peptide 1; MASH, metabolic dysfunction–associated steatohepatitis.